Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer

Aaron M. Le Beau, Sai Duriseti, Stephanie T. Murphy, Francois Pepin, Byron Hann, Joe W. Gray, Henry F. Van Brocklin, Charles S. Craik

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Components of the plasminogen activation system, which are overexpressed in aggressive breast cancer subtypes, offer appealing targets for development of new diagnostics and therapeutics. By comparing gene expression data in patient populations and cultured cell lines, we identified elevated levels of the urokinase plasminogen activation receptor (uPAR, PLAUR) in highly aggressive breast cancer subtypes and cell lines. Recombinant human anti-uPAR antagonistic antibodies exhibited potent binding in vitro to the surface of cancer cells expressing uPAR. In vivo these antibodies detected uPAR expression in triple negative breast cancer (TNBC) tumor xenografts using near infrared imaging and In single-photon emission computed tomography. Antibody-based uPAR imaging probes accurately detected small disseminated lesions in a tumor metastasis model, complementing the current clinical imaging standard F-fluorodeoxyglucose at detecting non-glucoseavid metastatic lesions. A monotherapy study using the antagonistic antibodies resulted in a significant decrease in tumor growth in a TNBC xenograft model. In addition, a radioimmunotherapy study, using the anti-uPAR antibodies conjugated to the therapeutic radioisotope 77Lu, found that they were effective at reducing tumor burden in vivo. Taken together, our results offer a preclinical proof of concept for uPAR targeting as a strategy for breast cancer diagnosis and therapy using this novel human antibody technology.

Original languageEnglish (US)
Pages (from-to)2070-2081
Number of pages12
JournalCancer Research
Volume73
Issue number7
DOIs
StatePublished - Apr 1 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer'. Together they form a unique fingerprint.

Cite this